The present invention relates to aseptic suspensions, physically stable and injectable through a 25 G needle or thinner, comprising crystalline, non-micronized 3-beta-hydroxy-5-alpha-pregnan-20-one particles, a mixture of acylglycerols and cholesterol, processes for preparing crystalline, non-micronized, 3-beta-hydroxy-5-alpha-pregnan-20-one suitable for such suspensions, as well as methods for manufacturing such suspensions.

Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cm.sup.3 and about 0.15 g/cm.sup.3, and/or a specific surface area (SSA) of at least 18 m.sup.2/g, 20 m.sup.2/g, 25 m.sup.2/g, 30 m.sup.2/g, 32 m.sup.2/g, 34 m.sup.2/g, or 35 m.sup.2/g. Methods for making and using such compositions are also provided.

A spray drying process and apparatus for drying a spray dryable liquid composition to a spray dried powder is described, in which the spray dryable liquid composition contains no carrier. The spray dryable liquid composition is processed at a solids concentration not exceeding 80% by weight, based on total weight of the spray dryable liquid composition, being atomized to generate an atomized spray of liquid particles of the spray dryable liquid composition into a spray drying chamber, in which the atomized spray is contacted with a stream of drying fluid flowed at temperature not exceeding 100° C. into the spray drying chamber, to form the spray dried powder.

The present disclosure relates to granules comprising an L-amino acid and a method for preparing the same.

The invention provides a composition which is suitable for the delivery of RNA, which composition comprises (i) particles contained in a liquid phase, wherein the particles comprise RNA and a lipid composition, and (ii) 1,2 propanediol. The lipid composition comprises (i-a) a cholesterol derivative, (i-b) a phosphoglyceride, and (i-c) a pegylated phosphoglyceride. Further provided are a method for preparing the composition, and a solid composition which is obtainable by freezing the composition wherein particles are contained in a liquid phase.

Provided is a composition comprising (i) a nano- or microparticle formulation of a therapeutically active agent which is suspended in a liquid phase, and (ii) at least one cryoprotective additive selected from C3-C5 alkanes substituted by one or two hydroxy groups which stabilizes the particle formulation. Further aspects relate to a solid composition which can be obtained by freezing the stabilized composition, and to processes for the preparation of the compositions in accordance with the invention.

The present disclosure relates generally to depot formulations of lurasidone and methods of making depot formulations of lurasidone. The depot formulations include a suspending agent and are highly syringeable.

Bee venom nanoparticles and methods of synthesizing bee venom nanoparticles are provided. The bee venom nanoparticles may be synthesized by drying bee venom, suspending the dried bee venom in a solvent to form a first bee venom solution, spraying the first bee venom solution into boiling water under ultrasonic conditions to form a bee venom solution including the bee venom nanoparticles, stirring the bee venom solution including the bee venom nanoparticles, and freeze-drying the bee venom solution. The resulting nanoparticles may be used in pharmaceutical compositions, and may be useful for their antimicrobial activities.

A topical formulation and method of using the formulation on animals including dogs is disclosed. The formulation is used to facilitate the healing of cuts, scrapes, abrasions, and other conditions often experienced by animals. A main ingredient of the formulation is sulfur in a high concentration.

Disclosed herein is a pharmaceutical composition for use in the treatment or prevention of radiation-induced fibrosis, wherein the composition comprises an extract of Trigonella foenum-graecum and optionally pharmaceutically acceptable additives.